All In Biotech

Drug Trial Radar · NCT04231513

A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

A Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Intravenous Infusions of E2814 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Apr 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Dec 16, 2019

Primary completion

Mar 9, 2023

Study completion Mar 9, 2023

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Jan 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety and tolerability of single and multiple intravenous infusions of E2814 in healthy adult participants.

Conditions

  • Healthy Volunteers

Interventions

  • E2814Drug

    E2814, intravenous infusion.

  • E2814-matched placeboDrug

    E2814-matched placebo, intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAD, Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to 113 days
  2. SAD, Number of Participants With Clinically Significant Laboratory ValuesTime frame: Up to 113 days
  3. SAD, Number of Participants With Clinically Significant Vital Signs ValuesTime frame: Up to 113 days
  4. SAD, Number of Participants With Clinically Significant Electrocardiogram (ECG) FindingsTime frame: Up to 113 days
  5. MAD, Number of Participants With TEAEs and SAEsTime frame: Up to 169 days
  6. MAD, Number of Participants With Clinically Significant Laboratory ValuesTime frame: Up to 169 days
  7. MAD, Number of Participants With Clinically Significant Vital Signs ValuesTime frame: Up to 169 days
  8. MAD, Number of Participants With Clinically Significant ECG FindingsTime frame: Up to 169 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • California Clinical Trials Medical Group/Parexel International

    Glendale, California

  • Worldwide Clinical Trials

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.